Becton, Dickinson and Company (NYSE:BDX) Holdings Raised by Massmutual Trust Co. FSB ADV

Massmutual Trust Co. FSB ADV lifted its stake in shares of Becton, Dickinson and Company (NYSE:BDX) by 56.2% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 603 shares of the medical instruments supplier’s stock after purchasing an additional 217 shares during the quarter. Massmutual Trust Co. FSB ADV’s holdings in Becton, Dickinson and Company were worth $141,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also modified their holdings of the stock. Livelsberger Financial Advisory purchased a new position in Becton, Dickinson and Company in the 4th quarter worth about $27,000. OLD Point Trust & Financial Services N A purchased a new position in Becton, Dickinson and Company during the 4th quarter valued at about $29,000. DiNuzzo Private Wealth Inc. purchased a new position in Becton, Dickinson and Company during the 4th quarter valued at about $30,000. Scarborough Advisors LLC purchased a new position in Becton, Dickinson and Company during the 4th quarter valued at about $32,000. Finally, Accordant Advisory Group Inc purchased a new position in Becton, Dickinson and Company during the 1st quarter valued at about $35,000. 86.97% of the stock is currently owned by institutional investors.

Becton, Dickinson and Company Price Performance

NYSE:BDX traded down $5.97 during trading hours on Monday, reaching $235.90. The company had a trading volume of 1,474,243 shares, compared to its average volume of 1,461,122. The stock has a 50-day moving average of $232.90 and a two-hundred day moving average of $236.30. Becton, Dickinson and Company has a one year low of $218.75 and a one year high of $284.48. The firm has a market capitalization of $68.18 billion, a PE ratio of 52.34, a PEG ratio of 2.06 and a beta of 0.42. The company has a quick ratio of 0.97, a current ratio of 1.85 and a debt-to-equity ratio of 0.70.

Becton, Dickinson and Company (NYSE:BDX) last announced its quarterly earnings results on Thursday, August 1st. The medical instruments supplier reported $3.50 earnings per share for the quarter, beating analysts’ consensus estimates of $3.31 by $0.19. Becton, Dickinson and Company had a return on equity of 14.49% and a net margin of 7.13%. The firm had revenue of $4.99 billion for the quarter, compared to analysts’ expectations of $5.08 billion. During the same period in the prior year, the business posted $2.96 earnings per share. The business’s revenue was up 2.3% compared to the same quarter last year. Analysts forecast that Becton, Dickinson and Company will post 13.06 earnings per share for the current year.

Becton, Dickinson and Company Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Monday, September 30th. Stockholders of record on Monday, September 9th will be issued a dividend of $0.95 per share. This represents a $3.80 annualized dividend and a dividend yield of 1.61%. The ex-dividend date is Monday, September 9th. Becton, Dickinson and Company’s payout ratio is presently 83.70%.

Insider Transactions at Becton, Dickinson and Company

In other news, EVP Roland Goette sold 3,300 shares of the stock in a transaction on Monday, May 13th. The stock was sold at an average price of $236.70, for a total transaction of $781,110.00. Following the sale, the executive vice president now owns 14,608 shares in the company, valued at $3,457,713.60. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In other news, EVP Roland Goette sold 3,300 shares of the company’s stock in a transaction on Monday, May 13th. The stock was sold at an average price of $236.70, for a total transaction of $781,110.00. Following the transaction, the executive vice president now owns 14,608 shares of the company’s stock, valued at $3,457,713.60. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP Thomas J. Spoerel sold 300 shares of the company’s stock in a transaction on Monday, June 10th. The shares were sold at an average price of $239.31, for a total value of $71,793.00. Following the transaction, the senior vice president now directly owns 1,976 shares in the company, valued at approximately $472,876.56. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 6,900 shares of company stock worth $1,634,112. Insiders own 0.31% of the company’s stock.

Wall Street Analysts Forecast Growth

BDX has been the topic of several research analyst reports. Barclays lifted their target price on Becton, Dickinson and Company from $305.00 to $312.00 and gave the company an “overweight” rating in a research note on Monday, May 6th. Raymond James lowered their price target on Becton, Dickinson and Company from $275.00 to $270.00 and set an “outperform” rating for the company in a research note on Friday. Stifel Nicolaus boosted their price target on Becton, Dickinson and Company from $270.00 to $280.00 and gave the company a “buy” rating in a research note on Friday, July 26th. Citigroup lowered their price target on Becton, Dickinson and Company from $260.00 to $255.00 and set a “neutral” rating for the company in a research note on Wednesday, July 10th. Finally, Evercore ISI lowered their price target on Becton, Dickinson and Company from $290.00 to $285.00 and set an “outperform” rating for the company in a research note on Tuesday, July 2nd. Two equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $279.50.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.